Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,868 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Interventions: Prednisone; Drug
Lead sponsor: John Levine; Other
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Conditions: Healthy Male Subjects
Interventions: Savolitinib, Fluvoxamine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Trauma, Hemorrhagic Shock
Interventions: Type AB plasma, Crystalloid fluid (standard of care for resuscitation); Biological · Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Streptococcal Pharyngitis
Interventions: Identifying group A strep carriers; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 5 Years to 15 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Arrest
Interventions: Preemptive Rapid Response Team intervention; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Pain, Depression, PTSD Symptoms, Sleep
Interventions: Traditional Chinese Acupuncture, Tennant™ Biomodulator Treatment, Transcutaneous electrical nerve stimulation (TENS) Treatment; Other · Device
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years to 60 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Healthy
Interventions: INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Neoplasms
Interventions: Regorafenib (BAY73-4506) + rifampin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity
Interventions: Oral Glucose Tolerance Test (OGTT), Assessment of dietary compliance, Stool sampling, Sodium Saccharin, Placebo, Lactisole; Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions: Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation); Combination Product
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Insulin Resistance, Diabetes
Interventions: Quantose IR and Quantose IGT analysis, HOMA IR the standard testing for insulin resistance; Diagnostic Test
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Sexually Transmitted Diseases
Interventions: Visby Medical Men's STI PCR Test Kit; Diagnostic Test
Lead sponsor: Visby Medical; Industry
Eligibility: 14 Years and older · Male only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Miami Lakes, Florida • Atlanta, Georgia + 2 more

Conditions: Ultrasound, Education, Virtual
Interventions: Butterfly handheld ultrasound machine; Combination Product
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Intubation; Difficult
Interventions: Miller blade, Truview PCD, Glidescope Cobolt; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Adolescents
Interventions: Adaptive Attention Training, Active Control, Low-dose Adaptive Attention Training; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 16 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Premature Birth, Preterm Birth
Interventions: PEA POD Infant Body Composition System; Device
Lead sponsor: Vishal Pandey, M.D.; Other
Eligibility: 23 Weeks to 42 Weeks
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Food Choices
Interventions: Ultra-Processed, Red, Icon-plus-text Labels, Contains Food Additives, Red, Icon-plus-text Labels, Warning Ultra-Processed, Red, Icon-plus-text Labels, Warning UPF, Red, Icon-plus-text Labels, Ultra-Processed, Yellow, Icon-plus-text Labels, Contains Food Additives, Yellow, Icon-plus-text Labels, Warning Ultra-Processed, Yellow, Icon-plus-text Labels, Warning UPF, Yellow, Icon-plus-text Labels, Ultra-Processed, Red, Text-only Labels, Contains Food Additives, Red, Text-only Labels, Warning Ultra-Processed, Red, Text-only Labels, Warning UPF, Red, Text-only Labels, Ultra-Processed, Yellow, Text-only Labels, Contains Food Additives, Yellow, Text-only Labels, Warning Ultra-Processed, Yellow, Text-only Labels, Warning UPF, Yellow, Text-only Labels; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 14,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Shock, Septic
Interventions: Lactated Ringer, Normal saline; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: C-Met Exon 14 Mutation
Interventions: Glumetinib; Drug
Lead sponsor: Haihe Biopharma Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Sleep Apnea, Glucose Metabolism Disorders
Interventions: Positive Airway Pressure, Supplemental Oxygen, Sham; Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 30 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Impaired Glucose Tolerance
Interventions: Sildenafil, Placebo, Hyperglycemic clamp, Euglycemic clamp; Drug · Diagnostic Test
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Infections, Bacterial
Interventions: GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Mass Casualty
Interventions: SonoSite Ultrasound; Procedure
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions: Minnelide™Capsules; Drug
Lead sponsor: Minneamrita Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more

Search by objective public record fields.

Pediatric GVHD Low Risk Steroid Taper Trial

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

Control of Major Bleeding After Trauma Study

GRoup A StrePtococcus

Patient Acuity Rating: a Tool to Prevent In-Hospital Cardiac Arrest

Comparing Acupuncture, BioModulator, and Transcutaneous Electrical Nerve Stimulation for Symptomatic Treatment of Chronic Pain.

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

Validation of a Novel Screening Test for Maternal Insulin Resistance

Clinical Evaluation of Visby Medical Men's Sexual Health Test

Tele-Ultrasound: VIrtual Hands-on Education for Novice Users

A Comparison Between Two Video Laryngoscopes,in Successfully Intubating Pediatric Mannequins w/wo Difficult Airways

Double-Blind Randomized Controlled Trial for the Evaluation of a Novel Adaptive Attention Training in Healthy Adolescents

Impact of Currently Recommended Postnatal Nutrition on Neonatal Body Composition

Perceptions of and Reactions to Ultra-Processed Menu Label Designs

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Obstructive Sleep Apnea and Glucose Metabolism

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

The Use of the FAST (Focused Abdominal Scan for Trauma) Scan by Paramedics in Mass Casualty Incidents

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors